Paolo Tarantino/X
Jun 3, 2025, 16:58
Paolo Tarantino Presented DATO-Base Trial Poster at ASCO 2025 on Breast Cancer CNS Metastases
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared on X by Dana-Farber’s Breast Oncology Center, adding:
“Patients with CNS disease need more. Need better therapies. Like novel ADCs!
DATO-Base is the first trial I designed when I moved to DFCI, mentored by Dr Sarah Sammons and Nancy Lin.
It tests Dato-DXd for CNS disease, with the LMD cohort fully accrued.
Results coming soon – stay tuned!”
Quoting Dana-Farber’s Breast Oncology Center‘s post:
“ASCO 2025 Poster Session on MBC DATO Base: A phase II study of Datopotamab deruxtecan for patients with Breast Cancer Brain Metastases or Leptomeningeal disease.”
More posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 07:24
Jul 19, 2025, 07:23
Jul 19, 2025, 07:22
Jul 19, 2025, 07:21
Jul 19, 2025, 02:39
Jul 18, 2025, 21:36
Jul 18, 2025, 21:35